Patents by Inventor Michael N. Teng

Michael N. Teng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences
    Patent number: 7709007
    Abstract: Attenuated respiratory syncytial virus (RSV) and vaccine compositions thereof are produced by introducing specific mutations associated with attenuating phenotypes into wild-type or RSV which is incompletely attenuated by cold-passage or introduction of mutations which produce virus having a temperature sensitive (ts) or cold adapted (ca) phenotype. Alternatively, recombinant RSV and vaccine compositions thereof incorporate attenuating and other mutations specifying desired structural and or phenotypic characteristics in an infectious RSV. Recombinant RSV incorporate desired mutations specified by insertion, deletion, substitution or rearrangement of a selected nucleotide sequence, gene, or gene segment in an infectious RSV clone. The immune system of an individual is stimulated to induce protection against natural RSV infection, or multivalently against infection by RSV and another pathogen, such as PIV, by administration of attenuated, biologically derived or recombinant RSV.
    Type: Grant
    Filed: September 2, 2004
    Date of Patent: May 4, 2010
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Brian R. Murphy, Peter L. Collins, Stephen S. Whitehead, Alexander A. Bukreyev, Katalin Juhasz, Michael N. Teng
  • Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences
    Patent number: 5993824
    Abstract: Attenuated respiratory syncytial virus (RSV) and vaccine compositions thereof are produced by introducing specific mutations associated with attenuating phenotypes into wild-type or RSV which is incompletely attenuated by cold-passage or introduction of mutations which produce virus having a temperature sensitive (ts) or cold adapted (ca) phenotype. Alternatively, recombinant RSV and vaccine compositions thereof incorporate attenuating and other mutations specifying desired structural and or phenotypic characteristics in an infectious RSV. Recombinant RSV incorporate desired mutations specified by insertion, deletion, substitution or rearrangement of a selected nucleotide sequence, gene, or gene segment in an infectious RSV clone. The immune system of an individual is stimulated to induce protection against natural RSV infection, or multivalently against infection by RSV and another pathogen, such as PIV, by administration of attenuated, biologically derived or recombinant RSV.
    Type: Grant
    Filed: July 15, 1997
    Date of Patent: November 30, 1999
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Brian R. Murphy, Peter L. Collins, Stephen S. Whitehead, Alexander A. Bukreyev, Katalin Juhasz, Michael N. Teng